)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
Helus Pharma
Helus Pharma (HELP) investor relations material
Helus Pharma Q1 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2027 earnings summary14 Aug, 2026
Executive summary
Appointed Michael Halstead as CEO to lead late-stage development and commercialization.
Completed enrollment in Phase 3 APPROACH study for HLP003 in MDD; topline data expected Q4 2026.
Advanced HLP004 for generalized anxiety disorder, with strong Phase 2 results and next study design due by end of Q3 2026.
Strengthened balance sheet with $50 million underwritten offering in June 2026.
Financial highlights
Cash totaled $166.4 million as of June 30, 2026.
Net loss was $47.8 million for Q1 2027, compared to $24.6 million in the same period last year.
Cash-based operating expenses were $37.5 million, up from $23.9 million year-over-year.
Cash flows used in operating activities were $37.1 million, compared to $29.5 million last year.
Increased expenses driven by advancement of HLP003 Phase 3 trials.
Outlook and guidance
Topline data for HLP003 Phase 3 APPROACH study expected in Q4 2026.
HLP004 next study design to be completed by end of Q3 2026.
HLP005 development candidate selection anticipated in second half of 2027.
HLP003 CYP450 profile and SSRI/SNRI compatibility
HLP004 3-hour discharge and GAD market potential
Burn rate trajectory for Phase 3 PARADIGM
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Helus Pharma
- Phase III data for a differentiated adjunctive depression therapy is expected in Q4.HELP
Canaccord Genuity's 46th Annual Growth Conference - FDA guidance and trial rigor shape psychedelic therapy development as key programs advance toward pivotal data.HELPTD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit 2024
- HLP003 and HLP004 show strong Phase 2 efficacy and safety, advancing toward pivotal trials.HELPCorporate presentation
- Net loss widened to $148M on higher R&D, but cash rose to $157M after major financings.HELPQ4 2026
- Phase III data for a novel adjunctive MDD therapy expected by year-end, supporting 2028 NDA plans.HELP7th Annual HCW Neuro Perspectives Hybrid Conference
- Lead MDD therapy shows high durability and strong efficacy, with pivotal phase III data due in Q4.HELPJefferies Global Healthcare Conference 2026
- HLP003 and HLP004 show strong clinical results and IP protection, targeting major mental health needs.HELPCorporate presentation
- Phase II data showed rapid, durable anxiety relief and high remission rates with strong safety.HELPStudy result
- 100% response and 71% remission at 12 months for 16mg; Phase 3 trials underway.HELPStatus Update
Next Helus Pharma earnings date
AGM 202622 Sep, 2026
Helus Pharma
Next Helus Pharma earnings date
AGM 202622 Sep, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage